• Login
    View Item 
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2015 RD&E publications
    • View Item
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2015 RD&E publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologists

    Thumbnail
    URI
    http://hdl.handle.net/11287/593932
    Author
    Mitchell, A. L.
    Goss, Lynne
    Mathiopoulou, L.
    Morris, M.
    Vaidya, Bijay
    Dickinson, A. J.
    Quinn, Anthony
    Dayan, C.
    McLaren, J.
    Hickey, J. L.
    Lazarus, J. H.
    Rose, G. E.
    Foley, P.
    MacEwen, C. J.
    Perros, P.
    Date
    2015-03-01
    Journal
    The Journal of clinical endocrinology and metabolism
    Type
    Journal Article
    Evaluation Studies
    Research Support, Non-U.S. Gov't
    Publisher
    Endocrine Society
    DOI
    10.1210/jc.2014-3146
    Metadata
    Show full item record
    Abstract
    CONTEXT: In active Graves' orbitopathy (GO), treatment can improve the final cosmetic and visual outcome. Diagnostic delay results in significant morbidity and increases patient dissatisfaction. However, it can be challenging for endocrinologists to recognize GO and decide who should be referred for ophthalmic care. OBJECTIVE: DiaGO, a clinical assessment tool, was developed for use in patients with Graves' disease (GD). The tool is designed to alert clinicians to the possibility of GO and prompt early ophthalmic assessment. DESIGN AND SETTING: A 20-point assessment tool was devised and tested on 104 GD patients: 27 "positive controls" with GO and 77 people with GD attending endocrine clinics over 17 months. Those scoring positively in endocrine clinics were referred for ophthalmic assessment. Both the appropriateness of the referral and subsequent treatment were assessed. RESULTS: Eighty-eight of the 104 patients (85%) were female (mean age, 48.5 y; range, 18-76 y). All 27 "controls" scored positively. Of the 77 people evaluated with GD, 27 (35%) scored above the threshold for referral and GO was confirmed in 24/26 (92%) who attended for specialist ophthalmic assessment. Twelve of these 24 (50%) were offered specific treatment following ophthalmology review. CONCLUSIONS: The timely diagnosis of GO is important because early intervention in active disease can improve prognosis. DiaGO alerts clinicians to the possibility of GO and prompts referral to specialist ophthalmic care. It is quick and easy to use and does not require specialist ophthalmic skills. Overall, half of those referred after use of DiaGO were offered specific treatment, suggesting its use might significantly improve the management of patients.
    Citation
    J Clin Endocrinol Metab. 2015 Mar;100(3):E458-62.
    Publisher URL
    http://press.endocrine.org/doi/10.1210/jc.2014-3146?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
    Collections
    • 2015 RD&E publications
    • Diabetes/Endocrine Services

    Browse

    All of RD&E Research RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2021  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV